

# Wing-Kin Syn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1420840/publications.pdf>

Version: 2024-02-01

83  
papers

3,999  
citations

172457

29  
h-index

123424

61  
g-index

86  
all docs

86  
docs citations

86  
times ranked

6192  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-Invasive Risk Stratification in NAFLD/NASH Patients for Screening EGD. <i>Clinical and Experimental Gastroenterology</i> , 2022, Volume 15, 1-3.	2.3	1
2	A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver. <i>Metabolites</i> , 2022, 12, 130.	2.9	2
3	Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis. <i>Nature Communications</i> , 2022, 13, 1096.	12.8	22
4	The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population. <i>Scientific Reports</i> , 2022, 12, 5123.	3.3	2
5	NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2147-2148.	2.3	1
6	Hepatokines and adipokines in NASH-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 442-457.	3.7	72
7	GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E30-E42.	3.5	12
8	Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. <i>Journal of Clinical Medicine</i> , 2021, 10, 1507.	2.4	9
9	Su336 UTILITY OF THE FASTâ„¢ SCORE IN IDENTIFYING US VETERANS WITH HIGH RISK NONALCOHOLIC STEATOHEPATITIS (NASH): A VALIDATION STUDY. <i>Gastroenterology</i> , 2021, 160, S-669.	1.3	0
10	Targeting myosin 1c inhibits murine hepatic fibrogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G1044-G1053.	3.4	5
11	Anti-Î±NFÎ± treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status. <i>Liver International</i> , 2021, 41, 2646-2658.	3.9	7
12	A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3676-3688.	2.3	11
13	Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth. <i>Hepatology</i> , 2021, 74, 2561-2579.	7.3	13
14	STARD1: a new rising StAR in cholesterol-mediated hepatocarcinogenesis. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 910-912.	1.5	0
15	Characteristics of amino acid substitutions within the Î±-determinant region of hepatitis B virus in chronically infected patients with coexisting HBsAg and anti-HBs. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 923-931.	1.5	5
16	Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E131-E144.	3.5	22
17	Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. <i>Cells</i> , 2020, 9, 2458.	4.1	40
18	Sa1003 ACCURACY OF FIBROSCAN CONTINUOUS ATTENUATION PARAMETER AND LIVER STIFFNESS IN ASSESSING STEATOSIS AND FIBROSIS IN USA VETERANS WITH NONALCOHOLIC FATTY LIVER DISEASE. <i>Gastroenterology</i> , 2020, 158, S-237.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease. <i>Aging Cell</i> , 2020, 19, e13183.	6.7	20
20	The Emerging Epidemic of Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: True, True, and Related?. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1885-1887.	2.3	4
21	Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?. <i>Gut</i> , 2020, 69, 975-976.	12.1	6
22	Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Bioscience Reports</i> , 2020, 40, .	2.4	21
23	Evolving Management Strategies for Nonalcoholic Fatty Liver Disease—Targeting Primary Care Physicians. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 611-618.	4.4	1
24	Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3394-3401.	2.3	6
25	THU-315-Non-cirrhotic patients with non-alcoholic fatty liver disease have impaired quality of life: Independently predicted by body mass index, diabetes and liver stiffness. <i>Journal of Hepatology</i> , 2019, 70, e299.	3.7	0
26	FRI-356-Single cell peripheral innate and adaptive immune signature of non-alcoholic steatohepatitis by cytometry time of flight. <i>Journal of Hepatology</i> , 2019, 70, e551-e552.	3.7	0
27	Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2351-2358.	2.3	35
28	Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature. <i>European Journal of Nutrition</i> , 2019, 58, 1785-1800.	3.9	17
29	Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. <i>Drugs</i> , 2019, 79, 903-927.	10.9	47
30	The motor protein Myo1c regulates transforming growth factor- $\beta$ signaling and fibrosis in podocytes. <i>Kidney International</i> , 2019, 96, 139-158.	5.2	20
31	Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth. <i>Digestive Diseases and Sciences</i> , 2019, 64, 606-608.	2.3	0
32	Current treatment options for nonalcoholic fatty liver disease. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 168-176.	2.3	14
33	Association of IFNL3 rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 433-439.	2.3	3
34	Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. <i>Frontline Gastroenterology</i> , 2018, 9, 115-121.	1.8	23
35	Thyroid hormone in the regulation of hepatocellular carcinoma and its microenvironment. <i>Cancer Letters</i> , 2018, 419, 175-186.	7.2	21
36	Iron Enhances Hepatic Fibrogenesis and Activates Transforming Growth Factor- $\beta$ Signaling in Murine Hepatic Stellate Cells. <i>American Journal of the Medical Sciences</i> , 2018, 355, 183-190.	1.1	32

#	ARTICLE	IF	CITATIONS
37	Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)â€”cause for concern?. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 138-142.	1.5	1
38	Atorvastatin provides a new lipidome improving early regeneration after partial hepatectomy in osteopontin deficient mice. <i>Scientific Reports</i> , 2018, 8, 14626.	3.3	1
39	Serum Interleukinâ€8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 1344-1355.	4.3	58
40	Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 150.	3.7	63
41	Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy138.	0.9	2
42	Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3187-3206.	2.3	53
43	Profile of drug resistance mutations in nucleos(t)ide analogue-experienced chronic hepatitis B patients in Tianjin, China. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 735-736.	2.5	0
44	Osteopontin splice variants and polymorphisms in cancer progression and prognosis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 93-108.A.	7.4	84
45	Gene expression profiling in bladder cancer identifies potential therapeutic targets. <i>International Journal of Oncology</i> , 2017, 50, 1147-1159.	3.3	17
46	Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. <i>American Journal of the Medical Sciences</i> , 2017, 354, 172-181.	1.1	56
47	Prediction of transcription factor bindings sites affected by SNPs located at the osteopontin promoter. <i>Data in Brief</i> , 2017, 14, 538-542.	1.0	7
48	Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. <i>Journal of Lipid Research</i> , 2017, 58, 1903-1915.	4.2	18
49	Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2017, 12, e0185902.	2.5	54
50	Osteopontinâ€”A Master Regulator of Epithelial-Mesenchymal Transition. <i>Journal of Clinical Medicine</i> , 2016, 5, 39.	2.4	80
51	Osteopontin Is Upregulated in Human and Murine Acute Schistosomiasis <i>Mansoni</i> . <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005057.	3.0	7
52	Human intrahepatic regulatory T cells are functional, require ILâ€2 from effector cells for survival, and are susceptible to Fas ligandâ€”mediated apoptosis. <i>Hepatology</i> , 2016, 64, 138-150.	7.3	72
53	Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice. <i>Scientific Reports</i> , 2016, 6, 36586.	3.3	6
54	NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed?. <i>Visceral Medicine</i> , 2016, 32, 234-238.	1.3	22

#	ARTICLE	IF	CITATIONS
55	Serum osteopontin is a biomarker of severe fibrosis and portal hypertension in human and murine schistosomiasis mansoni. <i>International Journal for Parasitology</i> , 2016, 46, 829-832.	3.1	9
56	Hedgehog regulates yes-associated protein 1 in regenerating mouse liver. <i>Hepatology</i> , 2016, 64, 232-244.	7.3	94
57	Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 135-144.	3.8	39
58	Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies. <i>PLoS ONE</i> , 2016, 11, e0162286.	2.5	25
59	Pathogenic Mechanisms in Alcoholic Liver Disease (ALD): Emerging Role of Osteopontin. , 2016, , 63-70.		1
60	Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni. <i>Clinical Science</i> , 2015, 129, 875-883.	4.3	29
61	Higher Thyroid-Stimulating Hormone, Triiodothyronine and Thyroxine Values Are Associated with Better Outcome in Acute Liver Failure. <i>PLoS ONE</i> , 2015, 10, e0132189.	2.5	14
62	Hepatitis E Virus Infection as a Possible Cause of Acute Liver Failure in Europe. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1836-1842.e2.	4.4	83
63	Differential osteopontin functions: The role of osteopontin isoforms. <i>Hepatology</i> , 2015, 62, 323-324.	7.3	7
64	Vitamin D counteracts fibrogenic TGF- $\beta$ 2 signalling in human hepatic stellate cells both receptor-dependently and independently. <i>Gut</i> , 2015, 64, 791-799.	12.1	118
65	Role of liver progenitors in liver regeneration. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 48-58.	1.5	18
66	Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. <i>Clinical Science</i> , 2014, 126, 845-855.	4.3	22
67	Extrahepatic complications of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014, 59, 1174-1197.	7.3	478
68	Endoscopic management is the treatment of choice for bile leaks after liver resection. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 626-633.e1.	1.0	39
69	Mini-Laparoscopy Guided Liver Biopsy Increases Diagnostic Accuracy in Acute Liver Failure. <i>Digestion</i> , 2014, 90, 240-247.	2.3	21
70	TWEAK/Fn14 Signaling Is Required for Liver Regeneration after Partial Hepatectomy in Mice. <i>PLoS ONE</i> , 2014, 9, e83987.	2.5	58
71	Low Levels of Blood Lipids Are Associated with Etiology and Lethal Outcome in Acute Liver Failure. <i>PLoS ONE</i> , 2014, 9, e102351.	2.5	17
72	Utility of Osteopontin in Lineage Tracing Experiments. <i>Gastroenterology</i> , 2013, 145, 254-255.	1.3	4

#	ARTICLE	IF	CITATIONS
73	Role of liver progenitors in acute liver injury. <i>Frontiers in Physiology</i> , 2013, 4, 258.	2.8	41
74	Repair-associated inflammation in nonalcoholic fatty liver disease. <i>Clinical Medicine</i> , 2013, 13, s15-s19.	1.9	5
75	NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2012, 61, 1323-1329.	12.1	231
76	Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 53, 106-115.	7.3	224
77	Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. <i>International Journal of Cancer</i> , 2011, 128, 2436-2443.	5.1	425
78	Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 1998-2007.	7.3	254
79	Similarities and Differences in the Pathogenesis of Alcoholic and Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2009, 29, 200-210.	3.6	46
80	Role for hedgehog pathway in regulating growth and function of invariant NKT cells. <i>European Journal of Immunology</i> , 2009, 39, 1879-1892.	2.9	59
81	Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. <i>Liver International</i> , 2009, 29, 1262-1272.	3.9	26
82	Hedgehog-Mediated Epithelial-to-Mesenchymal Transition and Fibrogenic Repair in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2009, 137, 1478-1488.e8.	1.3	232
83	Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. <i>Journal of Clinical Investigation</i> , 2008, 118, 3331-42.	8.2	284